RBC initiates Eli Lilly at outperform RBC says the weight loss pharmaceutical maker is best positioned to fight obesity. "We ...
Novo Nordisk will set a $675/month US list price (effective January 1, 2027) for Wegovy, Ozempic, and Rybelsus, targeting affordability for high-deductible and coinsurance designs. Impacted doses ...
Moderator and TBJ reporter Lilly Egan (left to right), and Mentoring Monday 2026 panelists Jennifer Borrero, Dean of Students at Salem College, Emily Edwards, Chief Digital & Marketing Officer for ...
The AI in Life Science Market is anticipated to experience a remarkable compound annual growth rate (CAGR) of around 25% in the coming years, highlighting the increasing reliance on AI technologies ...
Here’s a waterfall that’ll make you question why you ever thought Kentucky was boring. Creation Falls sits in the Daniel Boone National Forest, looking like something from a nature calendar. The water ...
The Portfolio returned 0.87% in Q4 2025, trailing its benchmark as sector performance and AI volatility impacted results. Read the full analysis for more details.
Life science incubator part of UC Berkeley's wider ecosystem, which has consistently ranked the number one university ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...
A new ulcerative colitis diagnosis can feel overwhelming—but with thoughtful food choices, lifestyle strategies and ...
Investor's Business Daily on MSN
Vir Biotech catapults on its $1.71 billion deal with Astellas
Vir stock catapulted Tuesday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results